menu
    • menu
    [{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Minoryx Therapeutics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed

                            Minoryx Therapeutics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leriglitazone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Leriglitazone Meets Primary Endpoint in NEXUS Trial for Pediatric Cerebral Adrenoleukodystrophy

                            Details : MIN-102 (leriglitazone) is a novel oral selective PPAR gamma agonist with a potential first and best-in-class profile for CNS diseases, currently being investigated for cerebral Adrenoleukodystrophy.

                            Product Name : MIN-102

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 11, 2024

                            Lead Product(s) : Leriglitazone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oryzon Genomics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed

                            Oryzon Genomics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vafidemstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ORYZON Presents Safety and Efficacy Data of Vafidemstat from The Phase II SATEEN Trial in Multiple Sclerosis A...

                            Details : Eighteen MS patients were enrolled in this Phase II randomized, double-blind, placebo-controlled, parallel group, dose-finding trial that evaluated the safety and tolerability of two vafidemstat doses in relapse-remitting MS or secondary progressive MS p...

                            Product Name : ORY-2001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 13, 2021

                            Lead Product(s) : Vafidemstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oryzon Genomics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed

                            Oryzon Genomics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vafidemstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ORYZON Presents vafidemstat 12-month Clinical Data From its Phase IIa Trials ETHERAL and REIMAGINE-AD in Alzhe...

                            Details : By modulating the histone modifying enzyme LSD1, vafidemstat has been shown to have potential in Alzheimer’s and a range of other CNS diseases.

                            Product Name : ORY-2001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 03, 2021

                            Lead Product(s) : Vafidemstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oryzon Genomics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed

                            Oryzon Genomics

                            Spain arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vafidemstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer’s Disease

                            Details : REIMAGINE-AD is a Phase IIa study to assess the effect of vafidemstat in agitation-aggression in moderate and severe AD patients.

                            Product Name : ORY-2001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 04, 2020

                            Lead Product(s) : Vafidemstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth